RESEARCH PAPER
There is no correlation between the functional polymorphism S460C>T of vascular endothelial growth factor (VEGF) gene promoter and uncomplicated recurrent urinary tract infection among young women
 
More details
Hide details
1
Department of Internal Medicine, School of Medicine, Syiah Kuala University, Banda Aceh, Indonesia
 
2
Medical Research Unit, School of Medicine, Syiah Kuala University, Banda Aceh, Indonesia
 
3
Tropical Diseases Centre, School of Medicine, Syiah Kuala University, Banda Aceh, Indonesia
 
4
Department of Microbiology School of Medicine, Syiah Kuala University, Banda Aceh, Indonesia
 
5
Department of Internal Medicine, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia
 
6
Department of Histology and Cell Biology, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia
 
7
Department of Pharmacology, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia
 
 
Submission date: 2014-10-13
 
 
Acceptance date: 2015-03-12
 
 
Online publication date: 2015-04-19
 
 
Publication date: 2020-03-24
 
 
Corresponding author
Maimun Syukri   

Jl. T. Tanoeh Abe, Darussalam, Banda Aceh 23111, Indonesia. Tel.: +62 811 685 945; fax: +62 651 26090.
 
 
Pol. Ann. Med. 2015;22(1):5-10
 
KEYWORDS
ABSTRACT
Introduction:
The –460C>T polymorphism in vascular endothelial growth factor (VEGF) gene promoter (rs833061) has robust association with various diseases including renal parenchymal scarring following urinary tract infection (UTI). However, the association of this polymorphism with uncomplicated recurrent UTI (RUTI) is still unclear.

Aim:
The objective of this study was to assess the correlation between VEGF –460C>T polymorphism and uncomplicated RUTI among young women.

Material and methods:
Polymerase chain reaction – restriction fragment length polymorphism (PCR-RFLP) with BstU1 restriction enzyme – and DNA sequencing were used to determine the VEGF –460C>T polymorphism among 34 young adult women with uncomplicated RUTI and 34 healthy controls. Differences in genotype and allele frequencies between case and control groups were analyzed with x2 test or Fisher's exact test.

Results and discussion:
This study found that there was no significant difference in genotype frequencies between cases (CC 23.5%; CT 26.5%; TT 0%) and controls (CC 85.3%; CT 14.7%; AA 0%). Dominant model analysis found that there was no significant difference between uncomplicated RUTI and normal groups (P = 0.368). Similarly, allele analysis also found that there was no association between VEGF –460C>T polymorphism and uncomplicated RUTI (P = 0.398).

Conclusions:
This study found that there was no correlation between VEGF –460C>T polymorphism and uncomplicated RUTI among young women.

CONFLICT OF INTEREST
There is no conflict of interest.
REFERENCES (36)
1.
Bishop MC. Uncomplicated urinary tract infection. EAU Update Ser. 2004;2(3):143–150.
 
2.
Franco AVM. Recurrent urinary tract infection. Best Pract Res Clin Obstet Gynaecol. 2005;19(6):861–873.
 
3.
Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000;182(4):1177–1782.
 
4.
Syukri M, Sja'bani M, Soesatyo MHN, Astuti I, Imran I, Harapan H. The promoter region (G-800A and C-509T) polymorphisms of transforming growth factor-b1 gene among young women with recurrent urinary tract infection. Egypt J Hum Genet. 2014;15(2):125–130.
 
5.
Zaffanello M, Malerba G, Cataldi L, et al. Genetic risk for recurrent urinary tract infections in humans: a systematic review. J Biomed Biotechnol. 2010;2010:321082.
 
6.
Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrinol Rev. 2004;25(4):581–611.
 
7.
Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
 
8.
Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res. 2007;13(10):2825–2830.
 
9.
Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular endothelial growth factor (VEGF) and its role in nonendothelial cells: autocrine signalling by VEGF. In: Madame C. urie Bioscience Database. Austin, TX: Landes Bioscience; 2000.
 
10.
Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev. 2009;89(2):607–648.
 
11.
Taimeh Z, Loughran J, Birks EJ, Bolli R. Vascular endothelial growth factor in heart failure. Nat Rev Cardiol. 2013;10:519–530.
 
12.
Pagès G, Pouysségur J. Transcriptional regulation of the vascular endothelial growth factor gene – a concert of activating factors. Cardiovasc Res. 2005;65(3):564–573.
 
13.
Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 50UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 1999;60(12):1245–1249.
 
14.
Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12(8):1232–1235.
 
15.
Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812–816.
 
16.
Eng L, Azad AK, Habbous S, et al. Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clin Cancer Res. 2012;18(17):4526–4537.
 
17.
Hsieh YY, Chang CC, Tsai FJ, Yeh LS, Lin CC, Peng CT. T allele for VEGF gene-460 polymorphism at the 50-untranslated region: association with a higher susceptibility to endometriosis. J Reprod Med. 2004;49(6):468–472.
 
18.
Kim JG, Sohn SK, Chae YS, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol. 2007;18(6):1030–1036.
 
19.
Ku KT, Wan L, Peng HC, Tsai MH, Tsai CH, Tsai FJ. Vascular endothelial growth factor gene-460C/T polymorphism is a biomarker for oral cancer. Oral Oncol. 2005;41(5):497–502.
 
20.
Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes. 2004;53(3):861–864.
 
21.
Song N, Liu B, Wu J, et al. Vascular endothelial growth factor (VEGF) –2578C/A and –460C/T gene polymorphisms and lung cancer risk: a meta-analysis involving 11 case-control studies. Tumour Biol. 2014;35(1):859–870.
 
22.
Wongpiyabovorn J, Yooyongsatit S, Ruchusatsawat K, Avihingsanon Y, Hirankarn N. Association of the CTG (–2578/–460/+405) haplotype within the vascular endothelial growth factor gene with early-onset psoriasis. Tissue Antigens. 2008;72(5):458–463.
 
23.
Cotton SA, Gbadegesin RA, Williams S, Brenchiley PEC, Webb NJA. Role of TGB-b1 in renal parenchymal scarring following childhood urinary tract infection. Kidney Int. 2002;61:61–67.
 
24.
Yim HE, Bae IS, Yoo KH, Hong YS, Lee JW. Genetic control of VEGF and TGF-b1 gene polymorphisms in childhood urinary tract infection and vesicoureteral reflux. Pediatr Res. 2007;62(2):183–187.
 
25.
Hussein A, Askar E, Elsaeid M, Schaefer F. Functional polymorphisms in transforming growth factor-beta-1 (TGFbeta-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection. Nephrol Dial Transplant. 2010;25(3):779–785.
 
26.
Syukri M, Imran I, Harapan H, Sja'bani M, Astuti I, Soesatyo MHN. Comparison of serum C3 complement levels between young women with recurrent urinary tract infection and healthy women. Alex J Med. 2015;51(1):35–39.
 
27.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
 
28.
Anjum F, Kadri SM, Ahmad I, Ahmad S. A study of recurrent urinary tract infection among women attending out patient in S.M.H.S. Hospital, Srinagar, Kashmir, India. JK-Practitioner. 2004;11(4):272–273.
 
29.
Ghazal S, Musmar M, AL-Tell M. Epidimiology of aerobic bacterial infections among IUD (intrauterine device) users in the Northern West Bank. An-Najah Univ J Res (N Sc). 2004;18(1):13–24.
 
30.
Harapan H, Fajar JK, Wahyuniati N, Anand JR, Nambaru L, Jamil KF. Non-HLA gene polymorphisms and their implications on dengue virus infection. Egypt J Hum Genet. 2013;14(1):1–11.
 
31.
Khalilullah SA, Harapan H, Hasan NA, Winardi W, Ichsan I, Mulyadi M. Host genome polymorphisms and tuberculosis infection: what we have to say? Egypt J Chest Dis Tuberc. 2014;63(1):173–185.
 
32.
Harapan H, Fajar JK, Khalilullah SA, Winardi W, Jamil KF. Genetic polymorphisms of HLA and HLA-related proteins: implications on dengue virus infection. J Mosq Res. 2013;3(1):1–10.
 
33.
Almawi WY, Saldanha FL, Mahmood NA, Al-Zaman I, Sater MS, Mustafa FE. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. Hum Reprod. 2013;28(10):2628–2635.
 
34.
Emiru T, Beyene G, Tsegaye W, Melaku S. Associated risk factors of urinary tract infection among pregnant women at Felege Hiwot Referral Hospital, Bahir Dar, North West Ethiopia. BMC Res Notes. 2013;6:292.
 
35.
Schnarr J, Smaill F. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. Eur J Clin Invest. 2008;38(Suppl 2):50–57.
 
36.
Sobjanek M, Zabłotna M, Lesiak A, et al. The 21154 G/A VEGF gene polymorphism is associated with the incidence of basal cell carcinoma in patients from northern Poland. Arch Dermatol Res. 2014;306:539–544.
 
Journals System - logo
Scroll to top